A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében

Translated title of the contribution: Role of rosuvastatin in lipid-lowering therapy today

Tatjána Ábel, J. Fehér

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.

Original languageHungarian
Pages (from-to)1424-1428
Number of pages5
JournalOrvosi Hetilap
Volume151
Issue number35
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Secondary Prevention
C-Reactive Protein
LDL Cholesterol
HDL Cholesterol
Atherosclerosis
Triglycerides
Therapeutics
Rosuvastatin Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében. / Ábel, Tatjána; Fehér, J.

In: Orvosi Hetilap, Vol. 151, No. 35, 01.08.2010, p. 1424-1428.

Research output: Contribution to journalArticle

@article{cec846754a5b46d0b3b5c605bf84810b,
title = "A rosuvastatin klinikai jelentos{\'e}ge napjaink lipidol{\'o}giai gy{\'o}gyszerel{\'e}s{\'e}ben",
abstract = "Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.",
keywords = "atherosclerosis, cholesterol, therapy",
author = "Tatj{\'a}na {\'A}bel and J. Feh{\'e}r",
year = "2010",
month = "8",
day = "1",
doi = "10.1556/OH.2010.28937",
language = "Hungarian",
volume = "151",
pages = "1424--1428",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "35",

}

TY - JOUR

T1 - A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében

AU - Ábel, Tatjána

AU - Fehér, J.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.

AB - Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.

KW - atherosclerosis

KW - cholesterol

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=77956312518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956312518&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.28937

DO - 10.1556/OH.2010.28937

M3 - Article

C2 - 20719717

AN - SCOPUS:77956312518

VL - 151

SP - 1424

EP - 1428

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 35

ER -